Matinas BioPharma Holdings, Inc.

About Matinas Biopharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections.

Learn about matinas biopharma Learn about Aquarius Biotechnologies

Drug Pipeline

MAT2203, Matinas BioPharma's lead drug candidate, is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent).

Learn About Aquarius
Biotechnologies Pipeline

MAT2501, is an orally-administered, encochleated formulation of Amikacin (a broad spectrum aminoglycoside antibiotic agent) under development  for gram-negative and intracellular bacterial infections.

Learn About Aquarius
Biotechnologies Pipeline

Stock Snapshot






Investor Presentation

Investor Presentation

View our latest Corporate Presentation

View Presentation